Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03785574

Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule

Gestational Trophoblastic Neoplasia Clinical Trial

Official title:
Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule，A Prospective Multicentre Randomized Controlled Trial

Clinical Trial Summary

The purpose of present study is to provide clinical evidences for the appropriate management of molar pregnancy with lung nodule. The hydatidiform mole patients with lung nodule ≥1.0cm will be randomized into 2 groups: A. treated with chemotherapy immediately, B. follow up until hCG level met FIGO diagnostic criteria of GTN (B1) or hCG level declined to normal spontaneously (B2). Lung nodule <1.0cm will directly treated as group C

Clinical Trial Description

The hydatidiform mole patients with lung nodule ≥1.0cm will be randomized into 2 groups: A. treated with chemotherapy immediately, B. follow up until hCG level met FIGO diagnostic criteria of GTN (B1) or hCG level declined to normal spontaneously (B2). The clinical characteristics of patients were compared, especially chemotherapy cycles to achieve hCG normalization and failure to first-line chemotherapy. Lung nodule <1.0cm will directly treated as group C: follow up until hCG level met FIGO diagnostic criteria of GTN (C1) or hCG level declined to normal spontaneously (C2) ;

Study Design

Related Conditions & MeSH terms

  • Gestational Trophoblastic Disease
  • Gestational Trophoblastic Neoplasia
  • Hydatidiform Mole
Clinical Trial Details
NCT number NCT03785574
Study type Interventional
Source Women's Hospital School Of Medicine Zhejiang University
Contact Xiao Li, dortor
Phone 008657189992206
Email 5198008@zju.edu.cn
Status Recruiting
Phase N/A
Start date December 24, 2018
Completion date September 1, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04562558 - Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia N/A
Not yet recruiting NCT06020755 - Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 7 Phase 2
Recruiting NCT06028672 - Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6 N/A
Terminated NCT02664961 - Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) Phase 2
Withdrawn NCT05405192 - Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia Phase 2
Recruiting NCT03703271 - Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia Phase 3
Not yet recruiting NCT04303884 - Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP) Phase 2
Recruiting NCT05139095 - Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia Phase 2
Recruiting NCT05635344 - A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia Phase 2
Recruiting NCT04756713 - Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia Phase 3
Active, not recruiting NCT01823315 - Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia Phase 3
Not yet recruiting NCT06169644 - The Psychological Impact of GTN on Women Who Have Completed Chemotherapy Treatment
Recruiting NCT04812002 - Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy Phase 2